Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daunorubicin liposomal

Next Previous
X
Search
Drug Profile

Daunorubicin liposomal

Alternative Names: Daunorubicin citrate liposome injection; DaunoXome; VS 103

Latest Information Update: 24 Oct 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Developer Galen Limited; Gilead Sciences; Swedish Orphan Biovitrum
  • Class Anthracyclines; Antineoplastics; Cytostatic antibiotics
  • Mechanism of Action Apoptosis stimulants; RNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Kaposi's sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Kaposi's sarcoma
  • Discontinued Acute myeloid leukaemia; Brain cancer; Breast cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer

Most Recent Events

  • 15 Nov 2012 Daunorubicin liposomal receives orphan drug status for Acute myeloid leukaemia in European Union
  • 24 Feb 2012 Galen Ltd. acquires daunorubicin liposomal (DaunoXome®) from Gilead Sciences
  • 14 Jan 2010 Biovitrum has merged with Swedish Orphan to form Swedish Orphan Biovitrum

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top